Our discoveries- FGF inhibitors
Dobecure arises in summer 2017 as a tool to lead to the market the investigation developed all over the years from its scientific board members with the FGF inhibitors.
Based on the preclinical and clinical investigations, developed since the late 80’s, it has been developed the registration dossier of the FGF inhibitors for the treatment of both presentation means (dry and wet) of age-related macular degeneration (AMD).
Moreover, Dobecure continues with the preclinical and clinical studies in other disorders where the FGF might be involved.
Scientific Board
Dr. Pedro Cuevas Sánchez
Head of Investigation
Chair of Cardiology
Universidad Alfonso X el Sabio
Dr. Luis Outeriño
Head of Ophtalmology Service Hospital Pio XII
Prof. Guillermo Giménez Gallego
Research Professor
Biological Investigations Centre
CESIC. – Spain
Rocío García Cañamaque
Clinical Research Expert
Funder – LeónResearch
Management Board
Diego Cuevas Bourdier
President
Dobecure, s.l.
Alfonso García Cañamaque
CEO
Dobecure, s.l.
Objectives
Provide an effective and safe treatment for those diseases that can be treated with inhibitors of fibroblast growth factor (anti-FGF) particularly in the inflammation and angiogenesis processes.
Out-licence those inhibitors and the clinical results for a better distribution in the global market, while contributing to treat diseases associated with inflammation and angiogenesis which prevalence affects more than 500 million people worldwide.
Continue investigating in new potential clinical uses for the synthetic inhibitors of fibroblast growth factor (FGF)
Investigate to cure.
Strategy
Our main challenge is the search for health.
We need the talent of the people to reach all our challenges.
Our perspective is global, to have an international impact.
Despite limiting ours activity to research, we believe that the ultimate goal must be the market